TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30764582
Drug: Hibiscus sabdariffa
Normalized name: HIBISCUS SABDARIFFA CALYX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscus sabdariffa calyces (HSC) extract (250 mL)
Study: 22420698
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no-treatment)
Study: 20830731
Drug: GAD-alum (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum (20 μg, two injections)
Study: 12698306
Drug: Diosmin 500
Normalized name: diosmin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin 500 mg once daily for 9 days before metronidazole administration
Study: 12698306
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg (two tablets) administered after diosmin pretreatment
Study: 12698306
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg (two tablets) administered alone (no diosmin pretreatment)
Study: 27681702
Drug: Rivastigmine capsule
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsule (1.5, 3, 4.5, and 6 mg/12 h)
Study: 23445266
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL physiologic saline)
Study: 21465735
Drug: 30-minute IV
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute IV infusion of zoledronic acid 4 mg (in 250 mL)
Study: 20005647
Drug: Dydrogesterone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (40 mg stat followed by 10 mg twice daily)
Study: 15343587
Drug: Insulin (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.05 units/kg)
Study: 10942153
Drug: Dipyridamole, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole, 200 mg p.o., 3‐4 h before surgery
Study: 2498074
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) suspension administered by nasogastric feeding tube during continuous enteral feeding infusion
Study: 30408325
Drug: Rats administered
Normalized name: rat skin extract
DrugBank: Rattus norvegicus skin (DB10608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rats administered 100 µmol kg-1 SFN
Study: 18454661
Drug: Locally delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally delivered doxycycline gel at baseline and 1 and 2 years as an adjunct to mechanical debridement
Study: 8936563
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole orally once daily for 10 days
Study: 8936563
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally once daily for 10 days
Study: 8464611
Drug: Mucin-containing lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucin-containing lozenge
Study: 16425789
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg once daily for 6 weeks
Study: 19230597
Drug: Ciprofloxacin (CFX)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CFX) 500 mg
Study: 19230597
Drug: Ibuprofen (IBF)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBF) 400 mg
Study: 16044790
Drug: Conventional evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional evaluation methods (cross‐sectional studies, observational studies, comparative studies, randomised controlled trials, and metaanalyses) applied to complementary and alternative medicine
Study: 11850711
Drug: Sequential sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential sargramostim and filgrastim
Study: 1781005
Drug: Norfloxacin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (7 days, twice daily)
Study: 21299925
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg methylprednisolone sodium succinate intravenously as a single bolus before surgery
Study: 11389862
Drug: Yoghurt (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoghurt (125 g twice daily for 8 weeks)
Study: 1977089
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg nocte
Study: 3596336
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg nocte
Study: 8344101
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg pem
Study: 10204754
Drug: Nefopam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20 mg)
Study: 27118212
Drug: Intramuscular paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular paracetamol (600 mg)
Study: 27118212
Drug: Intramuscular or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular or oral syrup paracetamol (1000 mg administered six-hourly)
Study: 27118212
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 1500 mg followed by 1000 mg maintenance dose
Study: 27118212
Drug: Paracetamol concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol concentrations
Study: 25018116
Drug: CYD dengue
Normalized name: CYD Dengue Virus Serotype 1 Live Attenuated Antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD dengue vaccine (three injections at months 0, 6, and 12)
Study: 25018116
Drug: CYD dengue
Normalized name: CYD Dengue Virus Serotype 1 Live Attenuated Antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD dengue vaccine
Study: 22198447
Drug: Augmentation (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation (N = 269)
Study: 29806663
Drug: Augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation
Study: 20085937
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with carboplatin and paclitaxel (PCB) with high blood pressure (HBP)
Study: 20085937
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with carboplatin and paclitaxel (PCB) without high blood pressure (HBP)
Study: 12521403
Drug: Nicotine 2-mg
Normalized name: nicotine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 2-mg sublingual tablet (n = 120)
Study: 10604733
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg or 800 mg twice a day)
Study: 7866815
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg twice daily for 12 weeks, followed by a maximum of four 5 mg tablets (20 mg max daily) for 12 weeks
Study: 29101134
Drug: Steam inhalation
Normalized name: Leader Hot Steam Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steam inhalation for recurrent sinusitis
Study: 28439716
Drug: Second-generation antipsychotic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotic drugs
Study: 15776065
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (specific drug not mentioned)
Study: 15776065
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (not specified)
Study: 11957789
Drug: Antioxidative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidative therapy
Study: 8635777
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) with amino acid based glucose electrolyte solution (Vamin) and lipid emulsion (Intralipid)
Study: 6233335
Drug: Isotretinoin 0.5
Normalized name: isotretinoin 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 0.5 mg/kg/day
Study: 29288402
Drug: Intensive prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive prevention in kindergarten with fluoride gel at school
Study: 29288402
Drug: Intensive prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive prevention in kindergarten without fluoride gel at school
Study: 29288402
Drug: Basic prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic prevention in kindergarten with fluoride gel at school
Study: 8889482
Drug: Hypotonic glucose‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic glucose‐electrolyte solution (H)
Study: 6297202
Drug: Glucocorticoids (dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (dexamethasone 2.0 mg/day for 3 days)
Study: 6297202
Drug: Exogenous ACTH1-24
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous ACTH1-24 administration
Study: 25730788
Drug: Cranoff (Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranoff (Test drug)
Study: 21087403
Drug: NGX-4010 (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (8% capsaicin dermal patch, 640 µg/cm²)
Study: 21087403
Drug: 0.04% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04% capsaicin control patch (3.2 µg/cm²)
Study: 20029098
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5-kg medicine ball)
Study: 11577259
Drug: Tirofiban/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban/heparin
Study: 21045817
Drug: Hemp Seed
Normalized name: Hemp Seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp Seed Pill (HSP) 7.5 g b.i.d.
Study: 19661478
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care including antidepressant
Study: 15114207
Drug: 4 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml/kg NaCl, 7.5%
Study: 15114207
Drug: 32 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 ml/kg NaCl, 0.9%
Study: 30131565
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (7 mg/24 h)
Study: 27798210
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral moxifloxacin
Study: 24432626
Drug: Qilin Pills
Normalized name: Qilib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilin Pills + levofloxacin
Study: 18316457
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba treatment for mild-moderate dementia
Study: 9604126
Drug: Rufinamide 600
Normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rufinamide 600 mg after a fat and protein rich breakfast
Study: 2513931
Drug: Needle aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle aspiration + Metronidazole 2.4 g/day for 10 days
Study: 2513931
Drug: Metronidazole 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 2.4 g/day for 10 days
Study: 30999260
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) monotherapy, starting dose 1600 mg QD (or 1200 mg if previously reduced), adjustable between 800–2400 mg QD.
Study: 28253839
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatments)
Study: 21897336
Drug: Ethyl alcohol-intoxicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl alcohol-intoxicated patients (mean ethyl alcohol, 251 [SD, 87] mg/dL)
Study: 18452779
Drug: Fluvastatin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 30 mg/day plus conventional calcium-channel blocker (CCB) therapy
Study: 8466367
Drug: Cefotaxime 4
Normalized name: cefotaxime 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 4 g/day for 21 days plus aminoglycoside for 10 days
Study: 26296296
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IPL and UVR
Study: 15378145
Drug: Colchicine administered
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine administered in 2 or 3 divided doses daily (Group I)
Study: 9743895
Drug: Org 31710
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 31710 (75 mg)
Study: 28831957
Drug: Walnut supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut supplementation (15% energy, average 43 g/d)
Study: 25925591
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 mg) intravenously prior to loading dose of ticagrelor (180 mg)
Study: 8236142
Drug: Sarulplase (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarulplase (both doses)
Study: 31360536
Drug: Tablet computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer technology's audio-visual facility
Study: 27074034
Drug: Combined H1R
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined H1R and H2R antagonist (fexofenadine and ranitidine)
Study: 17583098
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with grass allergen tablets (standardized tablet at different doses)
Study: 31046016
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of 0.01% atropine and +2.50‐diopter add center‐distance soft bifocal contact lenses (SBCL) for 2 weeks
Study: 25962165
Drug: BG00010 (neublastin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG00010 (neublastin, artemin, enovin) 0.3, 1, 3, 10, 25, 50, 100, 200, 400, or 800 μg/kg (intravenous) or 50 μg/kg (subcutaneous)
Study: 8069886
Drug: NaF dentifrice
Normalized name: DENTIFRICES
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF dentifrice brushed three times daily
Study: 8069886
Drug: Fluoride-releasing device
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-releasing device (FRD; 0.07 mg F/day) plus F‐free dentifrice
Study: 8069886
Drug: FRD (0.232
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRD (0.232 mg F/day) plus F‐free dentifrice
Study: 8069886
Drug: F‐free dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: F‐free dentifrice three times daily
Study: 2495079
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg combined with Warfarin
Study: 27576370
Drug: Phlebotomy (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy (6 ml/kg/2 weeks)
Study: 27576370
Drug: Deferasirox (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (for patients with baseline serum ferritin 1,000 ng/ml or higher)
Study: 27576370
Drug: Phlebotomy (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy (for patients with baseline serum ferritin 1,000 ng/ml or higher)
Study: 26598476
Drug: Risperidone (switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (switched from initial medication)
Study: 26598476
Drug: Lithium (switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (switched from initial medication)
Study: 15582920
Drug: Methylphenidate (16,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (16, 32 and 48 mg)
Study: 8306751
Drug: ICI 204,219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,219 (0.2 mg dose)
Study: 3769898
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine i.m.
Study: 31765004
Drug: Pharmacist-led education-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led education-based intervention to deprescribe inappropriate medications (sedative-hypnotics, first-generation antihistamines, selective nonsteroidal anti-inflammatory drugs, glyburide)
Study: 31765004
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose aspirin (100 mg) for primary prevention
Study: 28431432
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg total macular carotenoids
Study: 25510442
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg per day)
Study: 19624626
Drug: Remifentanil 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1, 2, 3, 4, or 5 microg.kg(‐1) co-administered with propofol 2.5 mg.kg(‐1)
Study: 9706948
Drug: Codeine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (1 mg/kg)
Study: 7653811
Drug: Acetaminophen (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (15 mg/kg)
Study: 11767272
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of physostigmine (100 microl, 2-8 mg/ml) for 1 min in healthy subjects
Study: 8516307
Drug: L‐697,661
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐697,661
Study: 3802717
Drug: Acute ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute ethanol administration
Study: 29701039
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Zhiyang (GV 9) Bazhen points combined with pantoprazole (40 mg once a day)
Study: 29701039
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg once a day)
Study: 8372265
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intravenous diclofenac
Study: 31599084
Drug: Vasopressor infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressor infusion via peripheral venous catheters (PVC)
Study: 31599084
Drug: Vasopressor infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressor infusion via central venous catheters (CVC)
Study: 21316535
Drug: MF59-adjuvanted H5N1
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) administered with a 2-week interval between doses
Study: 21316535
Drug: MF59-adjuvanted H5N1
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) administered with a 3-week interval between doses
Study: 21316535
Drug: MF59-adjuvanted H5N1
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses)
Study: 9509206
Drug: 1000 ml
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ml of compound sodium lactate solution during surgery
Study: 2494454
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (1.5 million units over 30 minutes)
Study: 2494454
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (rt-PA) (100 mg over three hours)
Study: 8507540
Drug: PAC plus
Normalized name: Nutritional Supplement Oral Powder for Suspension [PROPAC PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC plus SPG combination therapy
Study: 8507540
Drug: PAC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC therapy
Study: 30621742
Drug: Single-shot sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot sciatic nerve block with 2 mg/ml ropivacaine, 20 ml
Study: 21422239
Drug: Sodium 2,2
Normalized name: DISODIUM 2,2'-DIHYDROXY-4,4'-DIMETHOXY-5,5'-DISULFOBENZOPHENONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium 2,2 dimethylbutyrate (SDMB) at doses of 2, 5, 10, and 20 mg/kg single dose or 5, 10, or 15 mg/kg daily for 14 days
Study: 17716544
Drug: Tomato-rich diet
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato-rich diet (300 g tomatoes daily for 1 month)
Study: 31017639
Drug: Integrated Prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Prolonged Exposure (I-PE) therapy
Study: 31017639
Drug: Integrated Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Coping Skills (I-CS) therapy
Study: 26236997
Drug: egg oral
Normalized name: Egg Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: egg oral immunotherapy (egg‐OIT) for 3 months (maintenance dose one undercooked egg every 48 hours)
Study: 18074149
Drug: Ceftibuten (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (9 mg/kg once daily for 14 days)
Study: 18074149
Drug: Ceftriaxone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (50 mg/kg once daily for 3 days) followed by Ceftibuten (for 11 days)
Study: 12650133
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 microg thrice weekly
Study: 12650133
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 microg once daily
Study: 3051550
Drug: Maloprim (pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maloprim (pyrimethamine and dapsone) administered fortnightly for 2 years
Study: 25003624
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones 80 mg/day
Study: 23605375
Drug: Control (non-treatment)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (non-treatment)
Study: 22097197
Drug: Safflower Injection
Normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower Injection (20 mL in 250 mL 5% glucose injection, administered intravenously once per day for 1-7 days)
Study: 22097197
Drug: Dextran-40 (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran-40 (administered intravenously once per day for 1-7 days)
Study: 22097197
Drug: Safflower Injection
Normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower Injection
Study: 16838647
Drug: Interferon as
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon as maintenance therapy following chemotherapy or autologous stem cell transplantation